Table 1.

Summary of patient characteristics by treatment

Treatment Group
	FLAG N=22	FA N=45	IA± G-CSF N=47
Parameters	Median (Range)	Median (Range)	Median (Range)	P value
Age	39 (18–74)	47 (18–80)	36 (16–83)	0.33
Sex (Male/Female)	10/12	20/25	29/18	0.20
ECOG PS	1 (0–2)	1 (0–4)	1 (0–4)	0.02
WBC	7.4 (1.1–91)	13 (0.6–93)	23.4 (1–226.5)	0.06
Platelet count	38 (6–119)	40 (12–330)	38 (6–183)	0.98
Hemoglobin	8.1 (3.4–11.9)	8.1 (2.5–13.1)	8.4 (3.7–12.3)	0.68
Creatinine	0.85 (0.6–1.2)	0.8 (0.5–2.8)	0.9 (0.6–2.9)	0.71
Total Bilirubin	0.5 (0.3–1.5)	0.5 (0.1–4.7)	0.6 (0.2–2.2)	0.23
Percentage bone marrow blast	42 (30–80)	51 (10–86)	54 (20–94)	0.43
Cytogenetics (N)
INV 16/T(8;21)	13/9	36/9	32/15	0.55

Abbreviations:

FLAG= fludarabine, cytarabine and G-CSF

FA= fludarabine, cytarabine

IA= idarubicin, cytarabine

ECOG= Eastern Co-operative Oncology Group

PS= performance status